Design, Preclinical Evaluation, and Clinical Translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma

Conclusion: 68Ga-FAPI-LM3 exhibited FAPI and SSTR2 dual-receptor–targeting properties both in vitro and in vivo, resulting in improved tumor uptake and retention compared with that observed with monomeric 68Ga-FAPI and 68Ga-DOTA-LM3. This study highlights the clinical feasibility of 68Ga-FAPI-LM3 PET/CT for NPC imaging.

Source: Journal of Nuclear Medicine - March 1, 2024 Category: Nuclear Medicine Authors: Zhao, L., Pang, Y., Fang, J., Chen, J., Zhou, Y., Sun, L., Wu, H., Guo, Z., Lin, Q., Chen, H. Tags: Clinical Investigations Source Type: research